Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.36 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25844882 | 0.81 | AOC3 (0.42) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL25844868 | 0.81 | AOC3 (0.63) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL506350 | 0.73 | EED (0.46) | ABCG2ALDH1A1HSD17B10HTR2AHTR2C | |
| SCHEMBL232439 | 0.72 | AOC3 (0.49) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL1045560 | 0.69 | L3MBTL1 (0.36) | ALDH1A1 | |
| SCHEMBL12593453 | 0.69 | AOC3 (0.44) | AOC3TXNRD1TXNRD3TXNRD2NQO2 | |
| SCHEMBL231938 | 0.68 | AOC3 (0.41) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL11778032 | 0.68 | AOC3 (0.45) | AOC3TXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL14370481 | 0.67 | AOC3 (0.42) | AOC3TXNRD1TXNRD3TXNRD2ALDH1A1 | |
| SCHEMBL11086762 | 0.67 | AOC3 (0.65) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1751108-B1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8415354-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| US-8372841-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2345640-A1 | Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7880001-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1751108-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005108368-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | AOC3 3565/4885TXNRD1 1315/4885TXNRD3 1154/4885 |
| US-20130338169-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | AOC3 1791/4885TXNRD1 1101/4885TXNRD3 846/4885 |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | AOC3 1791/4885TXNRD1 1101/4885TXNRD3 846/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | AOC3 3565/4885TXNRD1 1315/4885TXNRD3 1154/4885 |
| US-20120004206-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | AOC3 3565/4885TXNRD1 1315/4885TXNRD3 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.